The content on this site is intended for healthcare professionals only
Prof Max Topp talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the Bispecific T-cell engaging therapy for adult ALL patients.
Prof Topp states that following approvals the drug is now available around the globe and that it is complemented by other newly developed therapies.
He goes on to say how this bispecific technology could be used across haematology oncology but also in other areas.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
EHA 2024: Multiple myeloma roundup
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC
Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC
![Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )](https://cdn.ecancer.org/44737-m.jpg)
Pembrolizumab plus docetaxel used to treat patients with metastatic castration-resistant prostate cancer
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients
